Outcomes of elective cancer surgery during the COVID-19 pandemic crisis: an international, multicentre, observational cohort study (CovidSurg-Cancer)

The rapid emergence of the COVID-19 virus has led to a global impact on elective surgical care. We have very little evidence to guide us. The magnitude and effects of these changes are uncertain. The safety of operating on patients electively with the risks of COVID-19 postoperative pneumonia is unknown. High-quality data will allow policy planning at regional and hospital level for both this outbreak and future pandemics. CovidSurg-Cancer will run in parallel to CovidSurg (which is capturing outcomes of patients undergoing surgery for all indications with concurrent COVID-19).

In order to contribute to CovidSurg-Cancer you must first secure appropriate approvals and senior surgeon leadership, according to local regulations. This short protocol has been written to support that process. This investigator-led, non-commercial, non-interventional study is extremely low to zero risk. This study does not collect any patient identifiable information and data will not be analysed at hospital-level.

Any centre that performs elective cancer surgery and has been affected by COVID-19 is eligible for participation. Investigators may choose one or more cancer types from their centre from which to upload data. This study be performed prospectively, retrospectively or using a mixed model, dependent on the phase of COVID-19 infection in your hospital.

Mr Aneel Bhangu, MBChB PhD FRCS
Consultant Surgeon, University Hospital Birmingham, UK

CovidSurg-Cancer
Study Protocol V2.0

Primary aim
- To evaluate the 30-day COVID-19 infection rates in elective cancer surgery during the COVID-19 pandemic.

Secondary aims
- To compare the 30-day postoperative mortality rate in cancer surgery patients that develop COVID-19 infection versus those who do not.
- To explore the scale of resource constraints related to the COVID-19 pandemic, and their impact on outcomes of elective cancer surgery.
- To explore variation in the selection of patients for continuing elective cancer surgery during the COVID-19 pandemic.
- To evaluate the impact of the COVID-19 pandemic on treatment pathways for cancers with a decision for surgical resection with curative intent.
Inclusion criteria
Any centres performing elective cancer surgery are eligible for participation. Centres will be stratified according to their national burden of COVID-19 infections using data from the World Health Organisation.

CovidSurg-Cancer study will capture:
- Patients planned for curative cancer surgery that have surgery completed during the COVID-19 pandemic
- Patients planned for curative cancer surgery that have surgery delayed or cancelled during the COVID-19 pandemic

Patient inclusion criteria:
- Adults (age ≥18 years) with a confirmed diagnosis of an included cancer type
- Decision made for surgical management with a curative intent

Patient exclusion criteria:
- Surgery planned with non-curative intent
- Planned neoadjuvant therapy without a firm date for surgery, or awaiting restaging

Patient enrolment
Centres can elect to include one or more cancer types in the study, in any combination, depending on local expertise and capacity. Investigators can enrol patients with confirmed diagnoses of Colorectal, Oesophagogastric, Head & Neck, Lung, Hepatopancreatobiliary, Urological, Gynaecological, Breast cancers and soft-tissue or bone Sarcoma. As a rapid response study to the COVID-19 pandemic, included cancer types have evolved following a short pilot period.

Study period
Investigators should identify a start date, which represents the start of the emergence of COVID-19 in their hospitals. At that stage, they should capture all patients who have had a decision for surgery at this time point, and then all patients with a new diagnosis and with a decision to surgery for the next 3 months (representing the peak period of the COVID-19 pandemic). We envisage most sites completing registration before August 2020 and completing follow-up by December 2020. However, changes to dates may be necessary as the disease changes, and we may develop a third phase for longer follow-up in selected sites with the capacity to do so.

Figure 1. Timeline for patient identification within CovidSurg-Cancer
Primary outcome measure
● 30-day postoperative COVID-19 infection rate.

Secondary outcome measures
● 30-day postoperative mortality rate.
● Postoperative critical care utilisation rate in high-risk cancer surgery patients.
● Proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery.
● Proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery.

Follow-up period
● Outcomes for operated patients will be collected up to 30-days postoperatively (with Day 0 as the day of surgery).
● Outcomes for non-operated patients should be collected up to 3-months from their study entry.

Figure 2. Timing of outcome assessment in CovidSurg-Cancer

Data collection
Data will be collected and stored online through a secure server running the Research Electronic Data Capture (REDCap) web application. REDCap allows collaborators to enter and store data in a secure, encrypted system. A designated collaborator at each participating site will be provided with REDCap project server login details, allowing them to securely submit data on to the REDCap system. REDCap has previously been successfully used for a range of other international cohort studies led by the central unit, including the GlobalSurg (www.globalsurg.org) and European Society of Coloproctology Audits and Cohort studies (https://www.escp.eu.com/research/cohort-studies). The REDCap server is managed by the University of Birmingham, UK. Only anonymised data will be uploaded to the database. No patient identifiable data, and no specific dates will be collected.
Data collected will include baseline demographic data, cancer-specific data, timelines for dates of diagnosis, decision for surgery and operation or completion of follow-up (summarised at a week level), operative and nonoperative cancer-related treatment, treatment related to COVID-19 (where applicable), pathology and clinical outcome data. Restricted additional cancer group-specific data will be collected to support individual cancer-level analyses. Data can be collected prospectively, or retrospectively where required, depending on the COVID-19 status of your hospital. A centre-level survey will collect data on departmental decision making processes, and the impact of COVID-19 on elective surgical services in each included hospital.

**Roles within the data collection team**

The principal investigator at each site should identify a team to:
- Identify patients waiting for curative surgery at the estimated start date.
- Proactively identify patients with a new decision for curative surgery during the study window.
- Monitor this patient cohort at regular intervals (e.g. weekly) to check their status up to completion of follow-up.
- Acquire outcome data at 30 days postoperatively for operated patients, and 3-months from study entry for non-operated patients.

No limits to the size of this team are imposed, and can be flexible to local capacity and service demands.

**Local approvals**

The principal investigator at each participating site is responsible for obtaining necessary local approvals (e.g. service evaluation, audit approval, research ethics committee or institutional review board approval). Local approvals should cover inclusion of all cancer types within this study. Collaborators will be required to confirm that relevant local approval is in place at the time of uploading each patient record to the study database. The study will be carried out in accordance with national and international guidelines, as well as the basic principles of the protection of the rights and dignity of Human Beings, as set out in the Helsinki Declaration (64th Assembly Fortaleza, Brazil, in October 2013), and according to current legislation.

Where an audit approval is needed, this can be either registered as service evaluation, or to benchmark against an auditable standard. For example, NHS Delivering Cancer Waiting Times - Good Clinical Practice Guide (2014):
- A maximum of one month wait from the date between a decision to treat (DTT) to the first definitive treatment for all cancers (including surgery).


Prior to formal local study approval, collaborators may prospectively collect data on hard copy case report forms (available at [https://globalsurg.org/cancercovidsurg/](https://globalsurg.org/cancercovidsurg/)), but this should not be uploaded to the REDCap database until approval is confirmed.
Analysis
A detailed statistical analysis plan will be published online at globalsurg.org/cancercovidsurg. Analyses will be overseen by the independent data monitoring committee (DMC). Reports will include description of the primary and secondary outcomes in the cohort. Interim analyses will be performed as guided by the independent DMC, and rapidly disseminated to the global healthcare community using social media, blog sites and health education platforms. The first analysis will be performed once 100 patients have been entered onto the database, and the frequency of subsequent analyses will be agreed with the DMC. The decision to submit data for publication will be agreed by the CovidSurg-Cancer steering committee upon consultation with the DMC. Hospital-level data will not be released or published.

Authorship
All collaborators from sites who contribute at least one patient will be recognised on any resulting publications as PubMed-citable co-authors. Flexible to service demands, no authorship limits will be imposed at a centre level; as many collaborating investigators are required, and work to support the project will be recognised on all future outputs.

A corporate authorship model will be used under CovidSurg Collaborative group, for example: https://pubmed.ncbi.nlm.nih.gov/29452941.